menu
    • menu

    Company profile for Neurotech Pharmaceuticals

    NEW Drugs in Dev: 5
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Neurotech was founded in 2000 with a mission to deliver biological therapeutics, through a sustained release cell-based delivery device, to the back of the eye allowing for longer delivery of therapeutic protein drugs, thus eliminating the need for frequent injections or topical drops. The Company's most advanced clinical program is to develop a treatment for macular telangiectasia type 2 (MacTel).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Neurotech PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    900 Highland Corporate Drive Building 1 Cumberland, RI 02864
    Telephone
    Telephone
    401-333-3880
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.neurotechpharmaceuticals.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neurotech Secures Permanent J-Code For Encelto™ From October 1
    Neurotech Secures Permanent J-Code For Encelto™ From October 1

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250929127803/en/Neurotech-Granted-Permanent-J-Code-J3403-for-ENCELTO-revakinagene-taroretcel-lwey-Effective-October-1-2025

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    Neurotech Appoints Peter J. McDonnell to the Board of Directors
    Neurotech Appoints Peter J. McDonnell to the Board of Directors

    02 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250902208046/en/Neurotech-Appoints-Peter-J.-McDonnell-M.D.-to-the-Companys-Board-of-Directors

    BUSINESSWIRE
    02 Sep 2025
    Share Share
    First FDA-Approved MacTel Treatment Performed
    First FDA-Approved MacTel Treatment Performed

    11 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250811189087/en/First-FDA-Approved-Treatment-for-MacTel-Performed

    BUSINESSWIRE
    11 Aug 2025
    Share Share
    Neurotech Appoints Beth Marsh as Chief Commercial Officer
    Neurotech Appoints Beth Marsh as Chief Commercial Officer

    21 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250421666615/en/Neurotech-Appoints-Beth-Marsh-as-Chief-Commercial-Officer

    BUSINESSWIRE
    21 Apr 2025
    Share Share
    Orsini Exclusive Specialty Pharmacy for Cell Therapy Encelto
    Orsini Exclusive Specialty Pharmacy for Cell Therapy Encelto

    01 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orsini-selected-as-the-exclusive-specialty-pharmacy-for-cell-therapy-encelto-302416126.html

    PR NEWSWIRE
    01 Apr 2025
    Share Share
    Neurotech’s Encelto Approved by the FDA for Macular Telangiectasia
    Neurotech’s Encelto Approved by the FDA for Macular Telangiectasia

    06 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250306180680/en

    BUSINESSWIRE
    06 Mar 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search